01
FDA Investigator
Conducted pharmaceutical manufacturing inspections and evaluated operations at the facility level.
→
Firsthand perspective
FDA inspection. CDER compliance. Industry quality leadership.
Former FDA Investigator · CDER OMQ Compliance Officer · Founder, Tailwind Pharma
When FDA is asking the hard questions, know how they are likely to evaluate the answers.
Tailwind Pharma helps pharmaceutical and biotechnology manufacturers with FDA inspection readiness, Form FDA 483 responses, Warning Letters, CGMP remediation, and complex compliance decisions — so leaders can see the situation the way FDA is likely to evaluate it.
Tailwind helps teams evaluate facts, anticipate scrutiny, identify weaknesses, and make defensible decisions before, during, and after FDA action.
Former FDA inspection experience
CDER compliance decision-making
Industry quality leadership experience
FDA inspection announced — or investigators already on site?
Get inspection help nowA rare professional progression
Three perspectives on the same compliance decision
The inspection creates the record. Compliance review determines its significance. Industry leadership must make the correction work.
02
CDER Compliance Officer
Reviewed findings, company responses, remediation, regulatory significance, and potential escalation.
→03
Industry Quality Executive
Led quality organizations within real operational, financial, manufacturing, and supply constraints.
Tailwind brings all three perspectives to the same problem.
17+
Years FDA & industry experience
100+
Facility inspections conducted
50+
Enforcement cases handled
$4B
Global company quality oversight
Former FDA Field InvestigatorFormer CDER Office of Manufacturing QualityVP, Corporate Quality AssurancePharmD, BCSCPNetwork of former FDA colleagues
Start with the situation
What are you facing?
01FDA is in our facility right now02We received a Form FDA 48303We received a Warning Letter04We are preparing a BLA / PLI05We have a PAI coming06Our remediation program is not working07We need an independent compliance assessment08We need an FDA / GMP expert witness09We need senior quality leadership
Four ways to start
Engage Tailwind Pharma
Each engagement path explains who it helps, what the work covers, and what evidence is involved — so you can tell quickly whether it fits your situation.
01
An active FDA inspection or a Form FDA 483 in hand
- Who it helps
- For pharmaceutical manufacturers, CDMOs, and compounding facilities with FDA investigators onsite or a Form FDA 483 requiring a response.
- Scope
- Real-time inspection support, response strategy, escalation assessment, and executive counsel while the matter is live.
- Evidence
- The inspectional observations, your draft responses, and the investigation and batch records behind them.
02
PLI & BLA readiness for biologics
- Who it helps
- For biologics manufacturers, sponsors, and CDMOs preparing original BLA manufacturing evidence, a potential PLI, sterile fill-finish readiness, or a relevant biologics supplement/site change.
- Scope
- Application-to-site evidence alignment, biologics drug substance and fill-finish readiness where applicable, sponsor/CDMO responsibility mapping, and prioritized remediation agreed when the work is scoped.
- Evidence
- Relevant CMC commitments, procedures, executed batch records, validation evidence, laboratory controls, quality agreements, and inspection-retrieval workflows.
03
A scoped inspection-readiness assessment
- Who it helps
- For sites preparing for an FDA inspection or Pre-Approval Inspection, or leadership that wants an independent view before FDA forms its own.
- Scope
- A mock FDA inspection or independent compliance assessment, with deliverables — such as written observations and a prioritized remediation plan — agreed when the work is scoped.
- Evidence
- SOPs, batch records, deviation and CAPA files, data-integrity controls, and training records, reviewed the way an investigator would ask for them.
04
An independent investigation or CAPA review
- Who it helps
- For quality leaders who want an independent challenge of an investigation or CAPA plan before FDA or a customer reviews it.
- Scope
- Independent review of investigation rigor, root cause, CAPA effectiveness logic, systemic scope, and management rationale.
- Evidence
- Deviations, OOS and OOT investigations, CAPA plans, and the effectiveness checks proposed to close them.
A 15-minute introductory discussion to understand your situation and agree the next step. Technical review is scoped separately.
01 · How We Help
Where are you in the FDA lifecycle?
The need changes with the moment. Tailwind helps leaders respond to an active issue, prepare before FDA arrives, and build quality systems whose decisions and evidence can withstand scrutiny.
01
Respond
FDA inspection & enforcement strategy
483 and Warning Letter responses informed by firsthand experience evaluating commitments, remediation plans, and escalation risk through FDA's compliance process.
- Active FDA inspection support
- Form FDA 483 response strategy
- Warning Letter response and remediation
- Regulatory escalation assessment
- Executive compliance advisory
- View response services
02
Prepare
Inspection readiness before FDA arrives
PLI/BLA readiness, sterile fill-finish preparation, mock inspections, and gap assessments structured around the application, the site, and the evidence FDA may evaluate.
- PLI & BLA readiness for biologics
- Sterile fill-finish readiness where applicable
- Mock FDA inspections & readiness drills
- Quality system and GMP gap assessments
- Pre-Approval Inspection preparation
- Inspection war rooms
- Executive readiness assessments
- View PLI & BLA readiness
03
Sustain
Executive quality advisory that holds
Senior executive quality advice and governance support that helps management make durable compliance decisions without displacing the designated Quality Unit.
- Quality system remediation
- CAPA effectiveness and investigation improvement
- Management oversight and governance
- CDMO / CMO quality oversight
- Fractional executive quality leadership
- View remediation services
02
Who We Serve
Built for regulated manufacturers that need depth, not headcount
Pharmaceutical & biotechnology manufacturers
Inspection readiness, 483 and Warning Letter response, remediation, and executive quality advisory for commercial and clinical-stage manufacturers.
Sterile manufacturers, 503B outsourcing facilities & 503A compounding pharmacies
Aseptic and sterile compounding oversight, USP <795>, <797>, and <800> readiness, insanitary-conditions risk, investigation strategy, and inspection support — led by a board-certified sterile compounding pharmacist (BCSCP).
CDMOs, CMOs & emerging companies
API through fill-finish oversight, supplier quality programs, and preparation for FDA milestones such as Pre-Approval Inspections.
Legal, investment & consulting partners
Secondary support: expert witness testimony, regulatory due diligence, and white-label ex-FDA depth for project teams.
03 · How Engagements Work
Senior expertise, without the firm overhead
You work directly with the consultant doing the work — not an account manager. Four steps from first call to defensible deliverable.
01
15-minute triage call
A direct conversation about the observation, deadline, or gap you're facing — and an honest read on regulatory risk.
02
Scoped plan and clear commercial terms
You receive a written scope with deliverables and timeline. Defined projects are quoted as fixed fees; ad-hoc or embedded support uses agreed hourly, day, or retainer terms — always agreed up front.
03
Embedded execution
Work happens remote-first inside your systems, with onsite support when it matters. Former FDA colleagues are added for larger scopes.
04
Defensible handoff
You keep documentation an investigator can follow: clear rationale, escalation logic, and evidence that the fix will hold.
04 · Professional Background
About Joseph Lambert, PharmD, BCSCP
Experience across FDA field investigations, CDER compliance decision-making, and global pharmaceutical quality leadership.
Firsthand regulatory experience, translated into defensible quality decisions.
Professional Journey
Across nearly 17 years at FDA — as a pharmaceutical field investigator and later in CDER's Office of Manufacturing Quality — followed by corporate quality leadership, I bring a unique blend of regulatory insight and executive quality leadership. My industry career includes a role asVice President, Corporate Quality Assurance for a $4 billion worldwide pharmaceutical company, where I led global quality strategy, governance, and oversight across injectable biologics and complex parenteral products.
My FDA background spans quality inspections, CDER Office of Manufacturing Quality compliance oversight, investigations, Field Alert Reporting, Out-of-Specification (OOS) and consumer complaint investigations, and Quality Unit evaluation and management—with deep working knowledge of 21 CFR Part 211, ICH Q7/Q10, EU GMP expectations, Bioresearch Monitoring, and Pre-Approval Inspections.
Doctor of Pharmacy (PharmD)
Board Certified with extensive pharmaceutical education
Vice President, Corporate Quality Assurance
Led global quality strategy, governance, and oversight for a $4 billion worldwide pharmaceutical company, covering injectable biologics and complex parenteral products
FDA Field Investigator
8 years conducting pharmaceutical facility inspections
CDER Compliance Officer
8 years in FDA's Office of Manufacturing Quality
Corporate Pharmaceutical Experience
Hands-on experience inside a corporate pharmaceutical company, giving deep insight into the real-world challenges firms face
Board Certified Sterile Compounding Pharmacist (BCSCP)
Specialized credentialing in sterile compounding and aseptic practice
Regulatory Frameworks & Focus Areas
21 CFR Part 211
ICH Q7 / Q10
EU GMP
Bioresearch Monitoring
Pre-Approval Inspections
Field Alert Reporting
OOS Investigations
Supplier & CMO Quality
My focus is regulatory judgment, compliance strategy, and executive quality leadership: defensible decisions, clear escalation logic, and quality systems that stay compliant after the inspection ends. Alongside that work, I publish thought leadership through The Regulatory Mix and explore regulatory technology through Tailwind AI.
View full professional history on LinkedInThe inspection may last days. The consequences can last years.
Tailwind helps pharmaceutical leaders evaluate the facts, understand the regulatory significance, and make defensible decisions before the issue becomes more difficult to correct.
Direct Contact
Get In Touch
Prefer to reach out directly instead of booking a call?